TrialJournal of experimental & clinical cancer research : CR2022

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.

Stephen L Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.